Nanostructured Carrier System for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nanostructured carrier systems for nucleic acids face challenges such as cytotoxicity, immune response, complex production processes, and inefficient endosomal release, leading to suboptimal transfection efficiency and stability.
Innovation Solution
A nanostructured active ingredient carrier system comprising a shell polymer and a complexing polymer that forms an interaction complex with hydrophilic agents, allowing for early endosomal release through pH-dependent or enzymatic degradation, reducing cytotoxicity and improving interaction with cell membranes during transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic-hydrophobic substances and amphiphilic polymers are used for nucleic acid complexation, then nucleic acid protection and controlled release are improved, but cytotoxicity increases and immune response is triggered
Solution Approach 1:
The patent changes the chemical parameters of the polymer by using polyacrylamide with controlled degrees of substitution (0-70% quaternization, 0-70% carboxymethylation) to reduce cytotoxicity while maintaining nucleic acid complexation capability. This parameter optimization resolves the contradiction between protection reliability and cytotoxicity.
Solution Approach 2:
The patent creates a composite polymer system combining polyacrylamide backbone with multiple functional groups (quaternary ammonium, carboxymethyl) to achieve both nucleic acid binding and reduced immunogenicity. The composite structure integrates protective function with biocompatibility.
2Duration of action of stationary object
If polyethylene glycol is used in the carrier system, then stability and circulation time are improved, but immune response is triggered due to antibody formation
Solution Approach 1:
The patent removes polyethylene glycol from the carrier system entirely, replacing it with polyacrylamide-based polymers that provide similar stability without triggering immune responses. This extraction of the problematic component resolves the contradiction between circulation duration and immune response.
3Quantity of substance
If multiple types of polymers are used for nanoparticle formation, then encapsulation efficiency is improved, but production complexity increases
Solution Approach 1:
The patent merges multiple polymer functions into a single polyacrylamide-based polymer that provides nucleic acid complexation, structural integrity, and controlled release capabilities. This consolidation reduces production complexity while maintaining encapsulation efficiency.
Solution Approach 2:
The polyacrylamide polymer is designed with multi-functionality, serving as both the structural backbone and the active complexing agent for nucleic acids. This universal polymer replaces multiple specialized polymers, simplifying production while maintaining performance.
4Adaptability or versatility
If micellar systems are used for nucleic acid delivery, then dynamic adaptability is improved, but system stability decreases due to dissolution below critical micelle concentration
Solution Approach 1:
Instead of using dynamic micellar systems that dissolve at low concentrations, the patent inverts the approach by using stable polyacrylamide-based nanoparticles that maintain structural integrity across all concentrations. This inversion resolves the contradiction between adaptability and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves reduced cytotoxicity, efficient interaction with cell membranes, and early endosomal release of the active ingredient, enhancing transfection efficiency and stability of the nanostructured carrier system.
Implementation Method 1
complexation of nucleic acids by means of electrostatic interactions
Implementation Method 2
early endosomal release through pH-dependent or enzymatic degradation
Implementation Method 3
early endosomal release through pH-dependent or enzymatic degradation
Data Source
AI summary
The invention relates to a nanostructured active ingredient carrier system, in particular for reducing cytotoxic properties owing to the use of sheath polymer and the transport resulting therefrom, for interactions with cell membranes during the transport of hydrophilic constituents and, in connection therewith, the generation of an early endosomal release of the interaction complex from the carrier system. The problem addressed by the present invention is that of specifying a nanostructured active ingredient carrier system which avoids the disadvantages of the prior art and in particular permits a reduction in cytotoxic properties owing to the use of a sheath polymer and the transport resulting therefrom. This problem is solved in that a nanostructured active ingredient carrier system is provided in the form of a particle consisting of a carrier sheath, wherein the carrier sheath comprises at least one or more hydrophobic sheath polymers, one or more charged complexing polymers and one or more hydrophilic active ingredients, wherein the complexing polymer interacts with the active ingredient.